Information provided in this article reflects publicly available guidance as of the publication date and may not reflect the most current regulatory requirements
The launch of generic liraglutide (Teva, August 2025) and anticipated oral GLP-1 options (oral Wegovy approved December 2025, orforglipron pending) offer lower-cost alternatives that may simplify pharmacy benefit management
GLP-1 patient volume exhibited consistent and substantial growth throughout the observation period, with an initial 37.9% increase in 2019, ultimately reaching a 744.6% increase by 2023 relative to the 2018 baseline (Figure 1)
Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line
Our medical team provides thorough training for self-injection at home, or patients may choose to come in for in-office administration
This is precisely why the in-vivo studies that express the E-domain as part of an IGF-I isoform, rather than as a free fragment, are so valuable: they sidestep the assumption that a cleaved free peptide is the physiologically relevant species
)
&srotate=0)
